Phase II study of sequentially administered low-dose mitomycin-C (MMC) and irinotecan (CPT-11) in women with metastatic breast cancer (MBC)

Ewa Mrozek, J. Kolesar, D. Young, J. Allen, M. Villalona-Calero, C. L. Shapiro

Research output: Contribution to journal › Article › peer-review

16 Scopus citations

Fingerprint

Dive into the research topics of 'Phase II study of sequentially administered low-dose mitomycin-C (MMC) and irinotecan (CPT-11) in women with metastatic breast cancer (MBC)'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science